MX2019013536A - Compuestos para el tratamiento de los trastornos de resistencia sistemica a la insulina y el uso de los mismos. - Google Patents

Compuestos para el tratamiento de los trastornos de resistencia sistemica a la insulina y el uso de los mismos.

Info

Publication number
MX2019013536A
MX2019013536A MX2019013536A MX2019013536A MX2019013536A MX 2019013536 A MX2019013536 A MX 2019013536A MX 2019013536 A MX2019013536 A MX 2019013536A MX 2019013536 A MX2019013536 A MX 2019013536A MX 2019013536 A MX2019013536 A MX 2019013536A
Authority
MX
Mexico
Prior art keywords
treatment
insulin resistance
compounds
systemic insulin
resistance disorders
Prior art date
Application number
MX2019013536A
Other languages
English (en)
Inventor
G Traber Peter
Zomer Eliezer
Shechter Sharon
Nir Raphael
M Johnson Joseph
George Ryan
Slate Deirdre
Original Assignee
Galectin Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Sciences Llc filed Critical Galectin Sciences Llc
Publication of MX2019013536A publication Critical patent/MX2019013536A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

Los aspectos de la invención se relacionan con compuestos sintéticos novedosos para el tratamiento de las enfermedades metabólicas parcialmente asociadas con la resistencia sistémica a la insulina causada por el enlace de las proteínas de galectina y la inhibición de los receptores de insulina y TGFß1 que ocasionan alteraciones fisiológicas en las vías de la insulina.
MX2019013536A 2017-05-12 2018-05-11 Compuestos para el tratamiento de los trastornos de resistencia sistemica a la insulina y el uso de los mismos. MX2019013536A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762505544P 2017-05-12 2017-05-12
US201762579373P 2017-10-31 2017-10-31
PCT/US2018/032381 WO2018209276A1 (en) 2017-05-12 2018-05-11 Compounds for the treatment of systemic insulin resistance disorders and the use thereof

Publications (1)

Publication Number Publication Date
MX2019013536A true MX2019013536A (es) 2020-02-13

Family

ID=64105127

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013536A MX2019013536A (es) 2017-05-12 2018-05-11 Compuestos para el tratamiento de los trastornos de resistencia sistemica a la insulina y el uso de los mismos.

Country Status (10)

Country Link
US (1) US20200061095A1 (es)
EP (1) EP3621975A1 (es)
JP (1) JP2020519597A (es)
KR (1) KR20200015528A (es)
CN (1) CN111032670A (es)
AU (1) AU2018265813A1 (es)
BR (1) BR112019023733A2 (es)
CA (1) CA3062649A1 (es)
MX (1) MX2019013536A (es)
WO (1) WO2018209276A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11576924B2 (en) 2017-05-12 2023-02-14 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
AU2019416330A1 (en) 2018-12-27 2021-07-01 Glycomimetics, Inc. Galectin-3 inhibiting c-glycosides
WO2020210308A1 (en) * 2019-04-10 2020-10-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
KR20220044785A (ko) 2019-08-09 2022-04-11 이도르시아 파마슈티컬스 리미티드 (헤테로)아릴-메틸-티오-베타-d-갈락토피라노시드 유도체
US20220324847A1 (en) 2019-08-15 2022-10-13 Idorsia Pharmaceuticals Ltd 2-hydroxycycloalkane-1-carbamoyl derivatives
PL4021904T3 (pl) 2019-08-29 2024-05-13 Idorsia Pharmaceuticals Ltd Pochodne alfa-d-galaktopiranozydu
JP2023504199A (ja) * 2019-12-06 2023-02-01 トゥルーバインディング，インコーポレイテッド Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
CA3161794A1 (en) * 2019-12-24 2021-07-01 John L. Magnani Galectin-3 inhibiting c-glycoside ketones, ethers, and alcohols
US20230192672A1 (en) * 2020-05-05 2023-06-22 Bristol Myers Squibb Small molecule inhibitors of galectin-3
IL301815A (en) 2020-10-06 2023-06-01 Idorsia Pharmaceuticals Ltd Spiro history of alpha-D-galactopyranosides
TW202233609A (zh) 2020-11-02 2022-09-01 瑞士商愛杜西亞製藥有限公司 2-羥環烷-1-胺甲醯基衍生物
WO2022171594A1 (en) 2021-02-09 2022-08-18 Idorsia Pharmaceuticals Ltd Hydroxyheterocycloalkane-carbamoyl derivatives
KR20230154221A (ko) 2021-03-03 2023-11-07 이도르시아 파마슈티컬스 리미티드 트리아졸릴-메틸 치환된 알파-d-갈락토피라노시드 유도체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812681A1 (de) * 1988-04-16 1989-11-02 Bayer Ag Substituierte n-glycosylamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
SE0401301D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
CN104955471A (zh) * 2012-11-15 2015-09-30 塔夫斯大学 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒
JP6904906B2 (ja) * 2015-01-30 2021-07-21 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤

Also Published As

Publication number Publication date
KR20200015528A (ko) 2020-02-12
JP2020519597A (ja) 2020-07-02
CN111032670A (zh) 2020-04-17
US20200061095A1 (en) 2020-02-27
BR112019023733A2 (pt) 2020-05-26
CA3062649A1 (en) 2018-11-15
EP3621975A1 (en) 2020-03-18
WO2018209276A1 (en) 2018-11-15
AU2018265813A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
MX2019013536A (es) Compuestos para el tratamiento de los trastornos de resistencia sistemica a la insulina y el uso de los mismos.
IL274162A (en) Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
PH12016500675B1 (en) Acylated glucagon analogues
PH12016500482A1 (en) Combination therapy with an anti-ang2 antibody and a cd40 agonist
MX2016004907A (es) Analogos del glucagon.
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
MD20170020A2 (ro) Compoziţii şi metode utilizate pentru tratamentul tulburărilor metabolice
MX2015015249A (es) Peptidos terapeuticos.
EA201692109A1 (ru) Варианты антител к фактору d и их применение
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
MX2016011072A (es) Derivado de pirazol amida.
MX2017012864A (es) Analogo acilado del glucagon.
TW201613964A (en) Improved A[beta] protofibril binding antibodies
IL277174A (en) Therapeutic combination of 1-4 BB agonists with anti-CD20 antibodies
EP3688021A4 (en) Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
PH12020551006A1 (en) Anti-alpha synuclein antibodies
MX2018010683A (es) Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos.
LT3727423T (lt) Metabolinių sutrikimų gydymas fgf21 variantais
GB201612165D0 (en) Combinations for the treatment of type 2 diabetes
IL249485B (en) History of o-alkyl-benzylideneguanidine and therapeutic use for the treatment of disorders associated with the accumulation of misfolded proteins
HK1210424A1 (en) Combinations of a glpir agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders glp1r 2
GB201707503D0 (en) New Therapy 3
GB201707207D0 (en) Treatment of type 1 diabetes
IL284074A (en) Decorin for use in the treatment of diabetes
SG10201912846PA (en) Therapeutic agent for non-motor symptoms associated with parkinson's disease